Neurodegenerative (NDG) illnesses, such as Alzheimer's disease and Parkinson's disease, are complex entities involving genetic, interactome, and environmental components. Recent molecular and high-throughput techniques give new light on the pathways and networks at the core of these complex disorders. This is necessary for the precision medicine paradigm to advance toward new molecular markers, systematic risk classification, and translational tailored medications. Significant advances in identifying, treating, and preventing neurodegenerative illnesses are predicted to arise from the deployment of a comprehensive precision medicine approach and the development of appropriate biomarkers. Therefore, after more than a decade of ineffective therapy trials and one of the lowest drug discovery success rates in medicine, it is imperative to study the idea of using omics to treat neurodegenerative illnesses.
The current data ranges from fundamental research to clinical/neuropathologic investigations, with the aim of stimulating fresh approaches to the comprehension, diagnosis, and treatment of NDG diseases. We solicit the submission of original papers. In addition, theoretical methods, such as Reviews, Perspectives, and Opinion papers on possible future prospects are welcome. This Research Topic encourages submissions that address the following subjects:
(1) Signs of aging in the central nervous system (genetic factors, epigenetic markers, telomeres).
(2) Identification of cell type-specific marker genes for aging.
(3) Identifying changed genes associated with NDG diseases.
(4) Quantifying alterations to distinct cell types in NDG diseases
(5) Identifying potential modifications to molecular pathways in NDG diseases (e.g., signaling pathways, inflammation, alternative splicing).
(6) Investigating new cell markers whose expression is changed in brain aging and NDG diseases.
(7) A comprehensive investigation of the alterations in alternative splicing in the aging brain, including a comparison with other external expression datasets (e.g., RNA-seq, from the Gene Expression Omnibus).
(8) Discussion regarding current advancements, prospective contexts of usage, and future views of genetic biomarkers in NDG diseases.
(9) Animal models for researching NDG diseases.
(10) Neuroscience translational research addressing different unresolved challenges in NDG diseases.
(11) Research that focuses on emerging fields of neuroscience, such as stem cell, neurotechnology (imaging, tractography, telemedicine), and personalized medicine.
Dr. Wael Mohamed
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
- High-Mobility Group Box 1 (HMGB1) Protein in Parkinson's Disease Research: A 10-Year Bibliometric AnalysisKhairiah Razali, Wael M. Y. MohamedJ. Integr. Neurosci. 2023, 22(4), 87; https://doi.org/10.31083/j.jin2204087(This article belongs to the Special Issue Genetics in Neurodegenerative Disorders: Modifying the Future)49Downloads184Views